327 related articles for article (PubMed ID: 17560512)
1. Advances in metabolic imaging for surgical oncology.
Iagaru A; Quon A
Surg Oncol Clin N Am; 2007 Apr; 16(2):273-92. PubMed ID: 17560512
[TBL] [Abstract][Full Text] [Related]
2. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
3. PET-CT in oncology.
Purandare NC; Rangarajan V
J Postgrad Med; 2010; 56(2):103-8. PubMed ID: 20622389
[TBL] [Abstract][Full Text] [Related]
4. PET and PET/CT in pediatric oncology.
Jadvar H; Connolly LP; Fahey FH; Shulkin BL
Semin Nucl Med; 2007 Sep; 37(5):316-31. PubMed ID: 17707239
[TBL] [Abstract][Full Text] [Related]
5. FDG PET/CT in oncology: "raising the bar".
Patel CN; Goldstone AR; Chowdhury FU; Scarsbrook AF
Clin Radiol; 2010 Jul; 65(7):522-35. PubMed ID: 20541652
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of PET/CT with tracers other than F-18-FDG in oncology: an evidence-based review.
Treglia G; Sadeghi R; Del Sole A; Giovanella L
Clin Transl Oncol; 2014 Sep; 16(9):770-5. PubMed ID: 24647843
[TBL] [Abstract][Full Text] [Related]
7. Standardization and quantification in PET/CT imaging: tracers beyond FDG.
Antunovic L; Rodari M; Rossi P; Chiti A
PET Clin; 2014 Jul; 9(3):259-66. PubMed ID: 25030389
[TBL] [Abstract][Full Text] [Related]
8. [FDG-PET/CT in oncology. German Guideline].
Krause BJ; Beyer T; Bockisch A; Delbeke D; Kotzerke J; Minkov V; Reiser M; Willich N
Nuklearmedizin; 2007; 46(6):291-301. PubMed ID: 18084685
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
[TBL] [Abstract][Full Text] [Related]
10. Non-[18F]FDG PET in clinical oncology.
Groves AM; Win T; Haim SB; Ell PJ
Lancet Oncol; 2007 Sep; 8(9):822-30. PubMed ID: 17765191
[TBL] [Abstract][Full Text] [Related]
11. PET beyond ¹⁸F-FDG: second generation PET tracers in clinical oncology.
Brouwers AH; Glaudemans AW; De Vries EF
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):1-3. PubMed ID: 25854554
[No Abstract] [Full Text] [Related]
12. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
13. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
[TBL] [Abstract][Full Text] [Related]
14. Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose.
Shiue CY; Welch MJ
Radiol Clin North Am; 2004 Nov; 42(6):1033-53, viii. PubMed ID: 15488556
[TBL] [Abstract][Full Text] [Related]
15. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG positron emission tomography in oncology: main indications.
Vercher-Conejero JL; Gámez Cenzano C
Radiologia; 2016; 58(4):303-19. PubMed ID: 27184919
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography: clinical applications in oncology. Part 1.
Kumar R; Nadig MR; Chauhan A
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1079-94. PubMed ID: 16336099
[TBL] [Abstract][Full Text] [Related]
18. Placental-site trophoblastic tumor and fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography.
Çerçi SS; Erdemoglu E; Bozkurt KK; Yalçn Y; Erdemoglu E
Hell J Nucl Med; 2015; 18(3):264-7. PubMed ID: 26574698
[TBL] [Abstract][Full Text] [Related]
19. Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET/computed tomography in detection of unknown primary tumor: a meta-analysis of the literature.
Dong MJ; Zhao K; Lin XT; Zhao J; Ruan LX; Liu ZF
Nucl Med Commun; 2008 Sep; 29(9):791-802. PubMed ID: 18677207
[TBL] [Abstract][Full Text] [Related]
20. Molecular positron emission tomography and PET/CT imaging in urological malignancies.
Powles T; Murray I; Brock C; Oliver T; Avril N
Eur Urol; 2007 Jun; 51(6):1511-20; discussion 1520-1. PubMed ID: 17275167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
